Compare BNR & PIII Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BNR | PIII |
|---|---|---|
| Founded | 2014 | 2015 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Medical Specialities | Medical/Nursing Services |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 126.5M | 33.8M |
| IPO Year | 2019 | 2021 |
| Metric | BNR | PIII |
|---|---|---|
| Price | $11.64 | $8.08 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $9.00 |
| AVG Volume (30 Days) | ★ 46.7K | 18.2K |
| Earning Date | 06-05-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $1,459,080,000.00 |
| Revenue This Year | $111.65 | $7.67 |
| Revenue Next Year | N/A | $2.36 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $6.79 | $1.52 |
| 52 Week High | $41.72 | $16.89 |
| Indicator | BNR | PIII |
|---|---|---|
| Relative Strength Index (RSI) | 57.68 | 31.90 |
| Support Level | $8.91 | $2.39 |
| Resistance Level | $12.89 | $11.55 |
| Average True Range (ATR) | 1.12 | 0.48 |
| MACD | 0.19 | -0.13 |
| Stochastic Oscillator | 61.56 | 0.41 |
Burning Rock Biotech Ltd is a cancer diagnostics company. The Group provides pharma research and development services, mainly cancer therapy selection tests services, companion diagnostics development services, and other service agreements with the combination of various customized tests services and analytical validation services, to pharmaceutical companies for developing new drugs for targeted therapies, immunotherapies on various types of cancers, and to hospitals for their studies on cancer diagnosis & treatment. It had three operating segments, including the Central laboratory business, the In-hospital business, & Pharma research & development services. It generates the majority of its revenue from the Central laboratory business. Its products are Pan-HEME, OncoScreen-WES, & others.
P3 Health Partners Inc is a patient-centered and physician-led population health management company. P3's model aggregates and supports the community's existing healthcare resources to build a network of community providers working together to deliver coordinated and integrated care to patients with a shared commitment to improving patient outcomes, lowering cost, and delivering experience for all. It includes utilization management, care management, disease education, and maintenance of a quality improvement and quality management program for members assigned to the Company. The Company is also responsible for the credentialing of its providers, processing and payment of claims, and the establishment of a provider network for certain health plans.